Coronavirus: Pfizer, BioNTech apply for EU approval of vaccine

The US Centers for Disease Control and prevention have confirmed that myocarditis and pericarditis can occur after mRNA vaccination in young people. But the cases are rare. Medical experts still recommend the shots.

BioNTech and Pfizer said an extra dose of their jab could boost immunity against the coronavirus delta variant. South Korea raised pandemic restrictions as cases hit the "maximum crisis level." Follow DW for the latest.

The Biovac Institute reached a deal with Pfizer to prepare and deliver vaccine doses for the continent. It comes amid an increase of cases in Africa, where just 2% of the population have received a first dose.

Researchers say two shots of either BioNTech-Pfizer or AstraZeneca vaccines are highly effective against variants. Elsewhere, China has declined to follow an investigation into the virus's origins. Follow DW for more.

After developing a coronavirus vaccine in record time, the German pharmaceutical company aims to start trialing a malaria shot next year using the same breakthrough mRNA technology.

Vaccines from both drugmakers have been approved in the EU for children from 12 to 17 years of age. Elsewhere, Australia continues its battle against the delta variant. Follow DW for the latest.

The announcement comes as coronavirus cases among children surge in the United States and other parts of the world.

The FDA's limited approval comes weeks after US President Joe Biden's administration announced a sweeping plan that would allow nearly all American adults to get a third shot.

The BioNTech/Pfizer vaccine for 5 to 11 year olds could be approved in the US as early as October. Meanwhile, Australia plans to stop paying workers affected by lockdowns. Follow DW for the latest.

While the European Medicines Agency approved a third dose for people over 18-years-old, the agency said it was up to member states to decide whether to use them.

BioNTech and Pfizer and said their vaccine is highly effective among children in the 5-11-year age group. Follow DW for the latest.

Younger people have a higher risk of heart inflammation with a Moderna shot, the country's vaccine advisory committee has said. It also advises on the BioNTech-Pfizer vaccine to all pregnant women.